



Immupharma PLC
("Immupharma" or the "Company")

Exercise of Warrants; Total Voting Rights

Immupharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £125,000.

The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company's existing issued ordinary shares.

An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Tuesday 16 September 2025.

The New Ordinary Shares represent 0.50% of the Company's enlarged issued share capital.

For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of Immupharma hereby notifies the market that following Admission, the Company's total issued share capital will consist of 502,223,932 Ordinary Shares with a nominal value of 1p each. This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.

Ends

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information please contact:

Immupharma PLC (www.immupharma.co.uk)
Tim McCarthy, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650
+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob Pountney

+44 (0) 20 3650 3650

SI Capital (Joint Broker)
Nick Emerson

+44 (0) 1483 413500


Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFSRADILIE